Epilepsy Clinical Trial
— EPISTOPIDEALOfficial title:
Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases
Tuberous sclerosis complex (TSC), affecting 1 in 6.000 live births, is characterized by the development of multisystem tumors. Seizures are frequent up to 80% of individuals. They usually start in infancy and are often drug resistant, with a high risk of intellectual disability and autism spectrum disorders. In animal models, preventive treatment before seizures onset significantly decreased the risk of epilepsy as well as associated comorbidities. EPISTOP randomized clinical trial (RCT) aimed to validate the effect of preventive therapy in patients with TSC diagnosed before clinical seizures with abnormal EEG, versus late standard therapy of epilepsy, administered after the seizures onset. This preventive therapy resulted in a significant better outcome in seizures and co-morbidities. However, this trial included few patients and did not allow to fully explore the secondary endpoints. Our goal within EPISTOP-IDEAL project is to benefit from joining clinical expertise of EPISTOP project and experts from IDEAL EU project on methodologies for CTs in small populations in order to consolidate the results of EPISTOP CT using uncertainty evaluation of the existing data of randomized and observational arms and adding important information from external data collected after EPISTOP ended. This collaboration aims to an optimal use of all available data (RCT, observational and external data collected with the same protocol). The goal is to demonstrate the added value of these methodologies in TSC CT and to their further use to rare epilepsies, and other rare diseases.
Status | Recruiting |
Enrollment | 35 |
Est. completion date | October 1, 2023 |
Est. primary completion date | March 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Months to 2 Years |
Eligibility | Inclusion Criteria: 1. Patients followed from 2013 to 2021 at the reference center for rare epilepsies with a diagnosis of tuberous sclerosis of Bourneville (based on Roach criteria and/or pathogenic variant identified in TSC1 or TSC2) 2. Start of follow-up at the reference center for rare epilepsies before the age of 4 months 3. Absence of epileptic seizures observed by relatives or on video EEG until inclusion Exclusion Criteria: 1. objection from their legal representatives 2. Antiepileptic treatment before or at the time of study entry 3. Seizure occurrence prior to the inclusion visit |
Country | Name | City | State |
---|---|---|---|
France | Rima Nabbout | Paris |
Lead Sponsor | Collaborator |
---|---|
Imagine Institute | Medical University of Warsaw, Ruhr University of Bochum, RWTH Aachen University |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time between birth and onset of seizures | To consolidate the primary outcome of the EPISTOP trial using the assessment of bias and external data, namely the impact of preventive treatment with vigabatrin on the time to first first epileptic seizure. | 2 years | |
Secondary | The duration of active epilepsy | To consolidate the secondary outcome measures of the EPISTOP trial using the assessment of bias and external data, namely the impact of preventive treatment with vigabatrin on the duration of active epilepsy | 2 years | |
Secondary | The number of individuals with active epilepsy at 2 years old | To consolidate the secondary outcome measures of the EPISTOP trial using the assessment of bias and external data, namely the impact of preventive treatment with vigabatrin on the number of individuals with active epilepsy at 2 years old | 2 years | |
Secondary | The number of individuals with drug-resistant epilepsy at 2 years old | To consolidate the secondary outcome measures of the EPISTOP trial using the assessment of bias and external data, namely the impact of preventive treatment with vigabatrin on the number of individuals with drug-resistant epilepsy at 2 years old | 2 years | |
Secondary | The number of individuals with EEG abnormalities at 2 years old | To consolidate the secondary outcome measures of the EPISTOP trial using the assessment of bias and external data, namely the impact of preventive treatment with vigabatrin on the number of individuals with EEG abnormalities at 2 years old | 2 years | |
Secondary | The psychomotor development at 24 months | To consolidate the secondary outcome measures of the EPISTOP trial using the assessment of bias and external data, namely the impact of preventive treatment with vigabatrin on psychomotor development | through study completion, an average of 2 years | |
Secondary | The number of individuals with hypsarrhythmia at 24 months on EEG | To consolidate the secondary outcome measures of the EPISTOP trial using the assessment of bias and external data, namely the impact of preventive treatment with vigabatrin on psychomotor development on the number of individuals with hypsarrhythmia at 24 months on EEG | through study completion, an average of 2 years | |
Secondary | The number of individuals with West syndrome before 24 months of age | To consolidate the secondary outcome measures of the EPISTOP trial using the assessment of bias and external data, namely the impact of preventive treatment with vigabatrin on psychomotor development on the number of individuals with West syndrome before 24 months of age | through study completion, an average of 2 years | |
Secondary | The number of individuals with autism spectrum disorders (ASD) | To consolidate the secondary outcome measures of the EPISTOP trial using the assessment of bias and external data, namely the impact of preventive treatment with vigabatrin on psychomotor development on the number of individuals with ASD | through study completion, an average of 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A | |
Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A |